Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.7
3.2
Journals
Life
Special Issues
Advances and Applications of Lung Transplantation
share announcement

Advances and Applications of Lung Transplantation

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Medical Research".

Deadline for manuscript submissions: closed (31 October 2023) | Viewed by 1464

Special Issue Editors

Dr. Ryuichi Waseda

E-Mail Website
Guest Editor
Department of General Thoracic, Breast, and Pediatric Surgery, Fukuoka University, Fukuoka, Japan
Interests: lung transplantation; general thoracic surgery; thoracic malignancy; airway surgery
Dr. So Miyahara

E-Mail Website
Guest Editor
Department of General Thoracic, Breast, and Pediatric Surgery, Fukuoka University, Fukuoka, Japan
Interests: lung transplantation; general thoracic surgery; pathology

Special Issue Information

Dear Colleagues,

Over four decades since the first successful lung transplant in 1983, various advances have been realized in lung transplantation as a last resort treatment for end-stage lung disease.

In the leading countries or institutions of lung transplantation, numerous innovative clinical and research activities have been implemented to further enhance the outcomes and expand the relevant applications. In addition, in less developed countries or institutions of lung transplantation, specific approaches adapted to their environment are required to stabilize the outcomes, increase caseloads, and launch new programs.

More recently, the indication of lung transplantation for end-stage respiratory failure with COVID-19, and the application of the surgical technique of lung transplantation to other thoracic surgeries are emerging areas of interest.

This Special Issue aims to address updated, fascinating and unique topics in lung transplantation, including the aspects not covered by regular journals or textbooks. Lung transplantation is a truly multi-factorial medical procedure. We welcome a variety of submissions from all disciplines involved in lung transplantation.

We look forward to your contribution.

Dr. Ryuichi Waseda
Dr. So Miyahara
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • organ procurement system
  • organ preservation
  • donor selection
  • donor management
  • recipient selection
  • recipient management (pre-, intra-, post-)
  • surgical techniques
  • clinical challenges
  • challenges in research
  • lung transplantation for COVID-19
  • application of surgical techniques to other surgical procedures
  • artificial lung
  • xenotransplanation

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

9 pages, 495 KiB  
Article
Everolimus Treatment for Chronic Lung Allograft Dysfunction in Lung Transplantation
by David Iturbe-Fernández, Alicia de Pablo Gafas, Víctor Manuel Mora Cuesta, Rodrigo Alonso Moralejo, Carlos Andrés Quezada Loaiza, Virginia Pérez González, Daniel López-Padilla and José M. Cifrián
Life 2024, 14(5), 603; https://doi.org/10.3390/life14050603 - 8 May 2024
Viewed by 318
Abstract
Our study aims to evaluate the effect of everolimus treatment on lung function in lung transplant (LT) patients with established chronic lung allograft dysfunction (CLAD). Methods: This retrospective study included LT patients in two reference LT units who started everolimus therapy to treat [...] Read more.
Our study aims to evaluate the effect of everolimus treatment on lung function in lung transplant (LT) patients with established chronic lung allograft dysfunction (CLAD). Methods: This retrospective study included LT patients in two reference LT units who started everolimus therapy to treat CLAD from October 2008 to October 2016. We assessed the variation in the maximum forced expiratory volume in the first second (FEV1) before and after the treatment. Results: Fifty-seven patients were included in this study. The variation in the FEV1 was −102.7 (149.6) mL/month before starting everolimus compared to −44.7 (109.6) mL/month within the first three months, +1.4 (63.5) mL/month until the sixth month, and −7.4 (46.2) mL/month until the twelfth month (p < 0.05). Glomerular filtrate remained unchanged after everolimus treatment [59.1 (17.5) mL/min per 1.73 m2 at baseline and 60.9 (19.6) mL/min per 1.73 m2, 57.7 (20.5) mL/min per 1.73 m2, and 57.3 (17.8) mL/min per 1.73 m2, at 1, 3, and 6 months, respectively] (p > 0.05). Everolimus was withdrawn in 22 (38.6%) patients. The median time to withdrawal was 14.1 (5.5–25.1) months. Conclusions: This study showed an improvement in FEV1 decline in patients with CLAD treated with everolimus. However, the drug was withdrawn in a high proportion of patients. Full article
(This article belongs to the Special Issue Advances and Applications of Lung Transplantation)
►▼ Show Figures

Figure 1

13 pages, 2080 KiB  
Article
Anti-CD20 Antibody and Calcineurin Inhibitor Combination Therapy Effectively Suppresses Antibody-Mediated Rejection in Murine Orthotopic Lung Transplantation
by Hiroki Matsumoto, Hidemi Suzuki, Takahiro Yamanaka, Taisuke Kaiho, Atsushi Hata, Terunaga Inage, Takamasa Ito, Toshiko Kamata, Kazuhisa Tanaka, Yuichi Sakairi, Shinichiro Motohashi and Ichiro Yoshino
Life 2023, 13(10), 2042; https://doi.org/10.3390/life13102042 - 11 Oct 2023
Cited by 1 | Viewed by 914
Abstract
Antibody-mediated rejection (AMR) is a risk factor for chronic lung allograft dysfunction, which impedes long-term survival after lung transplantation. There are no reports evaluating the efficacy of the single use of anti-CD20 antibodies (aCD20s) in addition to calcineurin inhibitors in preventing AMR. Thus, [...] Read more.
Antibody-mediated rejection (AMR) is a risk factor for chronic lung allograft dysfunction, which impedes long-term survival after lung transplantation. There are no reports evaluating the efficacy of the single use of anti-CD20 antibodies (aCD20s) in addition to calcineurin inhibitors in preventing AMR. Thus, this study aimed to evaluate the efficacy of aCD20 treatment in a murine orthotopic lung transplantation model. Murine left lung transplantation was performed using a major alloantigen strain mismatch model (BALBc (H-2d) → C57BL/6 (BL/6) (H-2b)). There were four groups: isograft (BL/6→BL/6) (Iso control), no-medication (Allo control), cyclosporine A (CyA) treated, and CyA plus murine aCD20 (CyA+aCD20) treated groups. Severe neutrophil capillaritis, arteritis, and positive lung C4d staining were observed in the allograft model and CyA-only-treated groups. These findings were significantly improved in the CyA+aCD20 group compared with those in the Allo control and CyA groups. The B cell population in the spleen, lymph node, and graft lung as well as the levels of serum donor-specific IgM and interferon γ were significantly lower in the CyA+aCD20 group than in the CyA group. Calcineurin inhibitor-mediated immunosuppression combined with aCD20 therapy effectively suppressed AMR in lung transplantation by reducing donor-specific antibodies and complement activation. Full article
(This article belongs to the Special Issue Advances and Applications of Lung Transplantation)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop